Streetbeat News

Analyst Ratings

SBCF

Truist Securities analyst Brandon King maintains a 'Buy' rating on Seacoast Banking (NASDAQ:SBCF) and raises the price target from $25 to $28.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2023 | 3:14 pm

OKE

Truist Securities analyst Neal Dingmann maintains a 'Buy' rating on ONEOK (NYSE:OKE) and raises the price target from $66 to $68.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2023 | 3:10 pm

AER

TD Cowen analyst Helane Becker maintains an Outperform rating on AerCap Holdings (NYSE:AER) and raises the price target from $80 to $90.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 01, 2023 | 3:09 pm

ON

Truist Securities analyst William Stein maintains a 'Buy' rating on ON Semiconductor (NASDAQ:ON) and has raised the price target from $93 to $122.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2023 | 3:06 pm

NEWR

Truist Securities analyst Joel Fishbein maintains a 'Hold' rating on New Relic (NEWR) and raises the price target from $77 to $87.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2023 | 3:06 pm

SBAC

TD Cowen analyst Gregory Williams maintains an Outperform rating on SBA Comms (NASDAQ:SBAC) but lowers the price target from $329 to $327.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 01, 2023 | 3:01 pm

NEWR

TD Cowen analyst J. Derrick Wood maintains a Market Perform rating on New Relic (NYSE:NEWR) and raises the price target from $73 to $87.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 01, 2023 | 2:58 pm

ANNX

Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Annexon (NASDAQ:ANNX) and maintained a price target of $18.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 2:57 pm

CDTX

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Cidara Therapeutics (NASDAQ:CDTX) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 2:57 pm

PRTG

Cantor Fitzgerald analyst Li Watsek has maintained an Overweight rating on Portage Biotech (NASDAQ:PRTG) but lowered the price target from $16 to $11.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 2:55 pm